ArticleVox sanguinis2026
Pathogen-reduced platelet concentrates in France: Impact on the risk of transfusion-transmitted infections, 2017-2024.
Article in Vox sanguinis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Assessment of the efficacy of large volume delayed sampling primary culture and pathogen reduction in preventing septic reactions from platelet transfusions.Transfusion · 2026Review
- Pathogen-reduced platelet concentrates in France: Impact on the risk of transfusion-transmitted infections, 2017-2024.Vox sanguinis · 2026Article
- Pathogen Reduction of Transfused Blood Components-The End of the Beginning Rather than the Beginning of the End.Pathogens (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesPathogen reduction (PR) using amotosalen-UVA was implemented for 100% of platelet concentrates (PCs) in France in November 2017. No bacterial testing was in place earlier. The impact of PR on the risk of transfusion-transmitted infections (TTIs) from November 2017 to December 2022 (vs. January 2013 to October 2017) has been published previously. To further assess the impact of PR implementation, the evaluation period was expanded to December 2024. MATERIALS AND
methodsPC-associated TTIs occurring in 2023 and 2024 were analysed and included in the assessment.
resultsTwo cases of PC-associated transfusion-transmitted bacterial infections (TTBIs) were reported. The first involved Bacillus mobilis in a split pooled whole blood-derived PC. This Grade 2 TTBI was diagnosed following identification of the same pathogen in the second PC unit, quarantined for failed swirling test. The second involved Staphylococcus ureilyticus in an apheresis PC transfused to a patient who subsequently died. TTBI frequency decreased from 1/97,098 PC (n = 15 over 5 years, 2 deaths) to 1/787,662 PC (n = 3, over 7 years, 1 death) after PR implementation (p < 0.001). No human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), human T-cell lymphotropic virus (HTLV) or arboviruses TTI were reported from 2013 to 2024. No further cases of PC-associated hepatitis E virus (HEV) TTI were reported, concomitantly to HEV-nucleic acid testing implementation. A PC-associated parvovirus B19 TTI occurred in 2024. The use of PR PCs facilitated PC supply during arboviral outbreaks.
conclusionThe reduction in PC-related TTBIs following PR implementation is confirmed. However, the recent occurrence of two severe TTBI cases highlights a persistent risk. Prevention of PR-PC-associated TTIs by non-enveloped viruses requires specific screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.